

Mylan to Pay \$465 Million Over EpiPen Medicaid Rebate Dispute



*Image by
Intropin*

Mylan NV has announced it will pay \$465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, **Reuters is reporting**. The announcement comes as the company is under intense scrutiny after a series of drastic price increases.

“Mylan has been lambasted by consumers and lawmakers for raising prices on the lifesaving EpiPen sixfold to over \$600 for a package of two in less than a decade, making the devices unaffordable for a growing number of families,” writes **Deena Beasley**.

At issue is whether Mylan made more money on EpiPen than warranted from state Medicaid programs by having it classified as a generic product. That classification yielded much smaller rebates to the government health plans. Beasley explains that the Medicaid rebate for a generic prescription drug is 13 percent, compared with a minimum 23.1 percent for a branded drug.

Read the article.